Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
Exagen Inc. accepted five abstracts at the ACR Convergence 2023, showcasing their autoimmune testing solutions.
09/28/2023 - 04:05 PM
SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California.
Below is the list of accepted abstracts, with links to each:
Sunday, November 12, 2023
Poster Presentation | Presented by Doruk Erkan | Abstract #0099 Title: Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune DiseasesSession Title: Poster Session ASession Time: 9:00 – 11:00am PT
Poster Presentation | Presented by Jennifer Rogers | Abstract #0557 Title: Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLESession Title: Poster Session ASession Time: 9:00 – 11:00am PT
Poster Presentation | Presented by Andrew Concoff| Abstract #0575 Title: The Real-World Utility of a Lupus Activity Monitoring Panel in the United States Community Rheumatologist PracticeSession Title: Poster Session ASession Time: 9:00 – 11:00am PT
Poster Presentation | Presented by Andrew Concoff| Abstract #0576 Title: Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional BiomarkersSession Title: Poster Session ASession Time: 9:00 – 11:00am PT
Tuesday, November 14, 2023
Poster Presentation | Presented by Vasileios Kyttaris| Abstract #2273 Title: Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision MedicineSession Title: Poster Session CSession Time: 9:00 – 11:00am PT
About Exagen Inc.
Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.
For more information, please visit Exagen.com and follow @ExagenInc on X.
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding our clinical research and development team’s scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE® test. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Relations
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com
760.560.1525
Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
XGN Rankings
#4255 Ranked by Stock Gains
XGN Stock Data
Industry
Dental Laboratories
Sector
Manufacturing
Tags
Health Services, Medical/Nursing Services, Manufacturing, Dental Laboratories
Country
US
City
Vista
About XGN
exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.